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SUMMARY
Introduction: Tumors arising in the lungs are in over 90% bronchogenic carcinomas that have been attributed
predominantly to tobacco smoking, asbestos or air pollution but little is known about endogenous factors that
could facilitate their development and invasiveness. The lungs originate embriologically from the same endo-
derm cells which form the epithelia lining the digestive tract, where gastrin is the major proliferative stimulus.
Aims: Since lung cancer patients were recruited mostly among smokers, who also have been found to exhibit
significantly higher infection rate of Helicobacter pylori (HP) infection than non-smokers and, as since the HP-
infected subjects show enhanced plasma levels of gastrin, we decided 1) to compare the seroprevalence of HP
and the expression of its cytotoxin, CagA, in lung cancer patients with those in the age- and gender-matched
controls without cancer; 2) to determine the gene expression for gastrin and its receptors (CCKB-R) in lung can-
cer, 3) to assess the gastrin levels in plasma bronchial lavage and in tumor tissue and 4) to examine the expres-
sion of cyclooxygenase (COX)-1 and COX-2 in cancer tissue resection margin and intact bronchial mucosa. 
Material and methods: The trial material included 50 patients with lung carcinoma and 100 age- and gender-
matched controls. Anti-HP and anti-CagA IgG seroprevalence was estimated by specific antisera using ELISA
tests. Gene expression of gastrin, CCKB-R, COX-1 and COX-2 was examined using RT-PCR, while gastrin was
measured by specific RIA.
Results: The seroprevalence of HP, especially that expressing CagA, is significantly higher in lung cancers than
in healthy controls. Both gastrin and CCKB-R mRNA were detected in the cancer tissue and at the resection
margin and similarly COX-2 mRNA was expressed in most cancers and resection margin but not in bronchial
mucosa where only COX-1 was found. The lung cancer tissue and resection margin contained many folds larg-
er amounts of immunoreactive gastrin than intact bronchial mucosa.
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INTRODUCTION
Numerous epidemiological studies demonstrated
that malignant tumors in the lungs are predominant-
ly bronchiogenic carcinomas, being the most com-
mon visceral malignancies accounting for about one
third of all cancer deaths in men and more than 7%
of all deaths in both sexes [1,2]. Statistical evidence
established a positive relationship between tobacco
smoking and lung cancer and a variety of substances
present in cigarette smoke have been considered as
potential carcinogens but efforts to reproduce the
lung cancer by exposing animals to smoke and its
ingredients have not been successful [3].
As in other cancers, various genetic mutations have
been detected by the time the lung tumor beco-
mes clinically apparent. Furthermore, an overex-
pression of cyclooxygenase-2 was reported in lung
cancer by numerous investigators suggesting that
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this enzyme could be responsible for abundant
release of eicosanoids, cell proliferation, angiogen-
esis and reduction in apoptosis [4—8], similarly as in
gastric cancer [9].
It is well known that lungs arise embriologically
from the same endoderm cells [10] that form the
lining of the gastrointestinal tract and possess simi-
lar neuro-endocrine and paracrine cells releasing
various hormonal peptides and their receptors
including gastrin releasing peptide (GRP) and gas-
trin [11—15].
Helicobacter pylori (HP) infection in the stomach is
known to be accompanied by a markedly enhan-
ced and prolonged release of gastrin [16] that has
been suggested to account for the development of
gastric cancer [16—18] and has been shown to
coexpress with COX-2 [5—9,19,20]. Since HP
infection was found to reach higher rate in smokers
than in non-smokers [21], we decided to assess the
relationship between HP infection and related gas-
trin release and COX-2 expression in lung cancero-
genesis. As cyclooxygenase-derived prostaglandins
(PG) have been suggested to stimulate angiogenesis
decrease apoptosis and tumor growth [20,23], it
was rationale to determine the expression of both
COX-1 and COX-2 in the lung carcinoma.
Therefore, the aims of this study were following:
1) to compare the seroprevalence of HP and its
cytotoxic protein, CagA, in lung cancer patients
with these in age- and gender-matched healthy
controls; 2) to determine the gene expression of
gastrin and its receptors (CCKB-R) in lung cancer;
3) to assess the gastrin content in the plasma and
bronchial lavage as well as in the lung tumor and
4) to examine the coexpression of COX-1 and
COX-2 in the lung cancer tissue.
We found that the lung cancer tissue contains
higher amounts of gastrin than the intact bronchial
mucosa and that cancer is capable of expressing
mRNA for gastrin and gastrin-receptors as well as
for COX-1 and COX-2 and to release large
amounts of the immunoreactive gastrin that could
stimulate locally (by autocrine and paracrine path-
ways) the tumor cell proliferation and possibly also
to induce COX-2 expression in cancer tissue.
MATERIAL AND METHODS
The studies were carried out on 50 histologically
verified lung carcinoma (45 men and 5 women)
with the median age of 64 years (range 47 to 82
years) and 100 controls (90 men, 10 women) with
the median age of 63 years (range from 47 to 82
years). Patients symptoms, age, gender, tumor site
and its histology were recorded at the Department
of Cardiosurgery of District Hospital of Cracow,
Poland and the laboratory tests were performed at
the Department of Physiology, Jagiellonian Univer-
sity Medical College, Cracow, Poland. Before the
surgery, gastroscopy was performed in some pa-
tients to obtain mucosal biopsy from corpus and
antral mucosa for RT-PCR analysis for the compari-
son of the expression of gastrin and its receptors
(CCKB-R). During the surgery, the large biopsy
samples were taken from the tumor, the resection
margin and intact bronchial mucosa at the remote
site from the cancer for by routine histological
examination to determine the stage and histologi-
cal type of the tumor. The tumors were identified
histologically as quamous cell carcinoma (80%) or
adenocarcinoma (20%) [1].
The HP infection status was assessed by our modi-
fication of capsulated minidose 13C-Urea Breath
Test (UBT) as described earlier [24] and/or by
determination of IgG antibodies to HP by enzyme
linked immunosorbent assay (ELISA) using com-
mercially available kit (EIAGEN HPIgG, Clone
Systems, Italy. Titers higher than 15 AU/ml were
considered positive (following the manufacturer
recommendations). IgG antibodies against CagA
were detected by ELISA using recombinant CagA
kindly provided Ora Vax Cambridge, USA as pre-
viously [16].
The samples of the tumor, the resection margin
and macroscopically intact bronchial mucosa taken
at the remote site from the tumor during surgery
were used for determination of the mRNA expres-
sion of gastrin, CCKB-R, COX-1 and COX-2 by
reverse transcription-polymerase chain reaction
(RT-PCR) as well as to assess the tissue content of
gastrin using RIA. For this purpose two larger tumor
(~100 mg), two tumor resection margin (~100 mg)
and two bronchial mucosa samples were taken and
frozen immediately in the liquid nitrogen for the
detection of the signals for gastrin and gastrin
receptors as well as COX-1 and COX-2 using
reverse transcriptase-polymerase chain reaction
(RT-PCR) as described earlier [25]. For measure-
ment of gastrin content, the tumor, the resection
margin and the intact mucosa samples were
homogenized in phosphate buffer at pH 7.7 and
0¡C for 10 s with Ultra-Turrax T-25, Ika Labortech-
nik, Staufen, Germany. The homogenized samples
were processed as for plasma gastrin RIA using gas-
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trin antiserum No 4562 (kindly donated by
Professor J. E. Rehfeldt of Copenhagen, Denmark)
in the final dilution of 1:140 000. The antibody
used recognized G-17 and G-34 equally. The sen-
sitivity of the present assay was 2.5 pmol/mL serum
equivalent to human G-17 [15]. Blood samples
were collected preoperatively from peripheral vein
under basal conditions and after separation of the
plasma they were stored at —70¡C for gastrin RIA as
described before [15,16]. Also the samples of
bronchial lavage were obtained after instillation of
about 50 ml of sterile saline into the bronchial tree
involved in the cancer, then succeed from the lung
and immediately centrifuged to separate the cellu-
lar components and stored and stored at —80¡C for
gastrin RIA.
RT-PCR and detection of amplified gene products
were performed using the above mentioned large
biopsy specimens obtained during surgery as
described before [15]. For this purpose, total cellular
RNA was isolated from these specimens using TRIzol
Reagent (Gibco BRL, UK). Briefly, tissue samples
placed in the liquid nitrogen and then transferred to
TRIzol Reagent and homogenized. After addition of
chloroform the aqueous phase was separated by
13000 rpm spin in 4¡C for 10 min. RNA was precip-
itated using isopropyl alcohol, washed with 75%
ethanol and resuspended in DEPC treated water. 1
mg of total cellular RNA was used for the synthesis
of cDNA in RT-PCR reaction (Promega Reverse
Transcription System). The final concentration of
components in 20 ml of total reaction volume was
as follows: 5 mM MgCl2, 1x Reverse Transcription
Buffer (10 mM Tries-HCl, 50 mM KCl, 0.1% Triton
X-100), 1 ml each dNTP 1U/ml Recombinant
RNasin Ribonuclease Inhibitor, 15 U/mg AMV
Reverse Transcriptase 0.5 mg Oligo (dT)15 Primer
per microgram RNA. Samples were incubated at
42¡C for 15 minutes and heated at 99¡C for 5 min-
utes followed by a 5 min incubation at 0—4¡C.
The PCR reactions were prepared in 1 x Dynazy-
me PCR buffer (Flowgen) with 40 mmol dNTPs
(Pharmacia) and 10 mmol of upper and lower
primers. The following primer pairs for PCR reac-
tion were used: 5Õ-GCC CAG CCT CTC ATC ATC
as a sense primer 3Õ-GGG GAC AGG GCT GAA
GTG - antisense for gastrin; 5Õ-TCT CGC GAG CTC
TAC TTA GGG as sense primer and 3Õ-GAA GTT
GCA CGT AGC AGC CA - antisense for CCKB; 5Õ-
AGC GGG AAA TCG TGC GTG as sense primer
and 3Õ-GGG TAC ATG GTG GTG CCG as anti-
sense for b-actin as well as 5Õ-GCAACACTGGAA-
CATGGCTA-3Õ as a sense primer and 5ÕACGC-
CACCATTCTGTCTTTG-3Õ as an antisense primer
for COX-1; and 5Õ-TCATTCACCAGGCAAATTGCTG-
GCAGGG-3Õ as a sense primer and 5Õ-ACAGTTCA
GTCGAACGTTCTTTTAGTAGTAC-3Õ as an antisen-
se primer for COX-2.
The thermal profile for all these reactions was the
same; 95¡C for 5 min before 40 cycles or 95¡C for
45 sec, 60¡C for 90 sec, and 72¡C for 90 sec. This
was followed by a single stage of 60¡C for 120 sec
and 72¡C for 180 sec. PCR products were analyzed
by agarose gel electrophoresis and abundance of
cDNA in each sample was estimated by video den-
sitometry analysis (Fotodyne, USA) using Gel-Pro
Analyzer program.
Statistical analysis 
The major groups were the HP-, CagA-seropositive
and serum and bronchial lavage gastrin concentra-
tions in patients with gastric cancer and controls. In
general, rank sum test, SpermanÕs rank test order
correlation was used for relation between indepen-
dent variables. A P value of less than 0.05 was
accepted as significant.
RESULTS
Figure 1 shows the HP seropositivity and CagA
seropositivity in 50 lung cancer patients and in 100
age- and gender-matched control subjects. The
prevalence of HP seropositivity reached ~90% in
lung cancer but only 64% in controls and this dif-
ference in HP seropositivity between cancers and
controls was statistically significant. The CagA
seropositivity in lung cancer patients was about
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Figure 1. The HP and CagA seropositivity in 50 lung patients and 100
controls. Mean–SEM of 20 tests in 50 lung cancer and 100
controls. Asterisk indicates significant (P<0.05) change as
compared to controls.
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thrice as high as in controls and this difference was
also statistically significant (Figure 2).
Plasma gastrin level in lung cancer patients was
about 73–14 pM and this was about three folds
higher than that in controls (22–7 pM). Similar dif-
ference in gastrin concentrations was found between
plasma and bronchial lavage (Figure 1). The gastrin
content in lung cancer tissue was nearly 3 ng/g of
wet tissue weight and it was about twice higher
than at the resection margin and about six times
more than in the macroscopically normal bronchial
mucosa (Figure 2). This difference between gastrin
concentration in lung cancer plasma and in healthy
controls as well as between the gastrin content in
tumor tissue, resection margin and intact bronchial
mucosa was highly statistically significant.
The tumor tissue of all cancer patients except one
(patients No 1) showed mRNA expression for gas-
trin and similar expression was detected in antral
biopsy samples taken from some of these patients
(Figure 3). The mRNA expression for gastrin recep-
tor (CCKB) signal was observed in seven out of ten
tested patients and it was usually less than that in
oxyntic mucosa of the same patients. The ratio of
gastrin mRNA to b-actin mRNA varied from case to
case and in one patients (No 10) it was similar in
the tumor tissue to that in antral mucosa but was
negligible in the corpus mucosa (data not shown).
The ratio of CCKB-receptor mRNA to b-actin
mRNA in lung tumor tissue or resection margin
reached the values smaller than that of intact gas-
tric corpus mucosa which is major target tissue of
gastrin and varied from case to case (Figure 3). This
ratio was negligible in the antrum mucosa and
these results have been omitted for the sake of
clarity.
Figure 4 shows the mRNA expression for COX-1
and COX-2 in the same cases as shown in Figure 3.
The COX-1 mRNA was expressed both in the can-
cer tissue, the resection margin as well as in intact
bronchial mucosa. COX-2 mRNA expression in all
tissue samples of lung cancer and its resection mar-
gin but in none of the intact bronchial mucosa. In
seven out of ten cases, the COX-2 mRNA expres-
sion was higher in the tumor tissue than in resec-
tion margin.
DISCUSSION
This study demonstrates for the first time that that
lung cancer is strongly associated with CagA-posi-
tive HP infection and shows that gastric HP infec-
tion in lung cancer patients is accompanied by a
significant increase in gastrin plasma and bronchial
lavage levels as well as by in increased mRNA
expression for gastrin and its receptors, as well as
for COX-1 and COX-2 in the tumor tissue.
The reason for the higher prevalence of HP infec-
tion in the lung cancer patients is not apparent but
the fact that the majority of cancer patients were
smokers, who are known to have higher HP infec-
tion rate [21], at least in heavily smoking Polish
population, indicates that smoking could be the
major factor of higher HP infection rate in lung
cancer patients.
The question remains whether this higher HP in-
fection rate plays any role in the pathogenesis of
lung cancer but the fact that this infection is
accompanied by an increased plasma level of gas-
trin [15,16], suggests that this hormone could con-
tribute to the lung cancerogenesis by inducing
higher mucosal cell proliferation of bronchial
epithelium leading to atrophy and induction of
COX-2 as it happens in most of gastric cancers
[25,26]. Previous studies showed that all classes of
bronchogenic carcinoma exhibit increased local
gastrin gene expression [12] and that gastrin con-
centration is elevated in serum and bronchoalveo-
lar lavage (BAL) fluid in patients with lung cancer
[27] and correlates with the disease extension [28]
though this was not confirmed by others [29]. In
addition, other studies indicate that gastrin is capa-
ble of mobilization of calcium ions and stimulation
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Figure 2. Plasma and bronchial lavage levels of gastrin in lung cancer
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of clonal growth of small cell lung cancer cells [30].
Our results confirm that, indeed, the plasma and
bronchial lavage fluid obtained from patients with
lung cancer exhibit significantly higher gastrin le-
vels than those in control subjects.
The main finding of the present study is the obser-
vation that the lung cancer tissue and resection
margin express mRNA for gastrin and CCKB-R and
contain several folds higher content of immunore-
active gastrin than the intact bronchial mucosa.
This suggests that the gastrin present in lung cancer
could contribute to the increased plasma levels of
this hormone, though the HP infection by itself
could explain, at least in part, the enhanced plas-
ma levels of this hormone originating from gastric
G cells as documented previously [15,17]. Our
finding that lung cancers exhibit higher expression
and content of gastrin and its receptors reminds
similar upregulation of gastrin biosynthesis already
described for gastric cancers [25] and colorectal
cancers [31]. As gastrin is known to be the most
potent mucosal growth promoting factor in gas-
trointestinal tract [32] (and possibly also in the
bronchial mucosa), it is tempting to assume that
this hormone could play a key role in the initiation
and the progression of cancer disease both in the
gastrointestinal tract and the lungs that embriologi-
cally originating from the same endoderm tube.
This is supported by recent report that a-amidated
gastrin peptides and their receptors are invariably
coexpressed in the adenocarcinoma of the pan-
creas that also originates from the same endoderm
as alimentary tract and the lungs [33]. This sug-
gests, again, that gastrin may be an autocrine factor
in carcinoma arising also from the pancreatic aci-
nar cells. This study is of particular interest because
it showed that in addition to amidated gastrin,
glycine extended gastrins as well as N-terminal pro-
gastrins were detected in the pancreatic cancer as
it was also found in colorectal cancer [31].
Epidemiological studies indicate that the use of
aspirin and other NSAID, whose major target is
cyclooxygenase, a rate-limiting enzyme converting
arachidonic acid to prostanoids, decreases the inci-
dence and mortality from gastrointestinal cancers
[23]. COX-2 has been found to occur in the lung
cancer [34] where it was held responsible for the
production of extensive amounts of prostaglandins,
tumor cell proliferation, angiogenesis, reduction in
apoptosis and tumor invasiveness. Assuming that
HP and gastrin are initiators of lung carcinogenesis,
the excessive production of prostanoids might be
implicated in promotion of this process and should
be a target for the chemotherapy using specific
COX-2 inhibitors [35]. Our results confirm the
gene expression of both COX-1 and COX-2 in the
lung cancer and thus, support the notion that,
indeed, COX-2 and COX-2 derived prostanoids
may play a role in the development of lung cancer
and should be a target of treatment using specific
COX-2 inhibitors. As the elimination of the initiator
of lung cancerogenesis such as increased gastrin
production seems to be possible, simply by eradi-
cation of HP, we propose, based on our present
data, that the HP infection in lung cancer patients
should be eliminated to reduce hypergastrinemia
and COX-2 expression, both factors that might be
responsible for the promotion of lung cancer.
CONCLUSIONS
This study provide an evidence that lung cancer is
capable of expressing gastrin and its receptors as
well as COX-2 that may be implicated in colonic
cancerogenesis. 
1. Lung cancer tissue and its resection margin
exhibit higher contents of gastrin and coexpress
more gastrin, its receptors and COX-2 than
intact bronchial mucosa.
2. HP infection may contribute to lung canceroge-
nesis via upregulation of gastrin and COX-2 that
may account for the stimulation of tumor growth
and angiogenesis, and 
3. HP positive patients developing lung cancer
should be considered for the HP eradication to
reduce the HP provoked hypergastrinemia and
COX-2 expression.
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